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Background: The metabotropic glutamate receptor 5 (mGluR5) is involved in various brain functions, including
memory, cognition and motor behavior. Regarding locomotor activity, we and others have demonstrated that
pharmacological antagonism of mGluR5 promotes hyperkinesia in mice. Moreover, increased locomotor activity can
also be observed in mice following the genetic deletion of mGluR5. However, it is still unclear which specific brain
substrates contribute to mGluR5-mediated regulation of motor function.
Results: Thus, to better understand the role of mGluR5 in motor control and to determine which neural substrates
are involved in this regulation we performed stereotactic microinfusions of the mGluR5 antagonist, MPEP, into
specific brain regions and submitted mice to the open field and rotarod apparatus. Our findings indicate that
mGluR5 blockage elicits distinct outcomes in terms of locomotor activity and motor coordination depending on
the brain region injected with mGluR5 antagonist. MPEP injection into either the dorsal striatum or dorsal
hippocampus resulted in increased locomotor activity, whereas MPEP injection into either the ventral striatum or
motor cortex resulted in hypokinesia. Moreover, MPEP injected into the olfactory bulb increased the distance mice
traveled in the center of the open field arena. With respect to motor coordination on the rotarod, injection of MPEP
into the motor cortex and olfactory bulb elicited decreased latency to fall.
Conclusions: Taken together, our data suggest that not only primarily motor neural substrates, but also limbic and
sensory structures are involved in mGluR5-mediated motor behavior.
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Glutamate is the major excitatory neurotransmitter in
the brain and is essential for a number of brain func-
tions, including memory, cognition and neuronal cell de-
velopment. Glutamate receptors are classified into two
main families: ionotropic glutamate receptors, which are
ligand-gated ion channels that mediate fast excitatory
neurotransmission, and metabotropic glutamate recep-
tors (mGluRs), which are members of the G protein-
coupled receptor (GPCR) family [1-4]. There are three
main types of ionotropic glutamate receptors, including
N-methyl-D-aspartate receptor (NMDA), alpha-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA),
and kainate receptors [5,2]. The mGluR subfamily of
GPCRs is comprised of eight different types of mGluRs* Correspondence: fmribeiro@icb.ufmg.br
1Departamento de Bioquimica e Imunologia, Instituto de Ciencias Biologicas,
Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil
Full list of author information is available at the end of the article
© 2015 Guimaraes et al.; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.that are sub-classified into three groups based on sequence
homology and G protein specificity [1,6,3,4]. Group I
mGluRs (mGluR1 and mGluR5) couple to Gαq/11 and pro-
mote the activation of phospholipase Cβ1, resulting in diac-
ylglycerol and inositol-1,4,5-triphosphate formation, release
of Ca2+ from intracellular stores and subsequent activation
of protein kinase C. In contrast, group II (mGluR2 and
mGluR3) and group III (mGluR4, mGluR6, mGluR7 and
mGluR8) mGluRs inhibit adenylyl cyclase via Gαi.
mGluR5 protein and mRNA have been detected in
various brain regions, including the olfactory bulb, cerebral
cortex, hippocampus, lateral septum, striatum, nucleus ac-
cumbens, inferior colliculus, and spinal trigeminal nuclei
[7,8]. Due to its widespread brain expression, mGluR5 is in-
volved in various brain functions, including spontaneous
locomotor activity and response to a new environment, as
well as anxiety and cognitive functions such as spatial
memory [9-12]. The role of mGluR5 in locomotor activity
is well established, as we and others have demonstrated thattral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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6-[phenylethynyl]-pyridine (MPEP) or 3-[(2-methyl-4-thia-
zolyl)ethynyl]pyridine (MTEP) administered peripherally
alter spontaneous locomotor activity and motor co-
ordination in rodents [13,14]. Moreover, increased
locomotor activity can also be observed in mGluR5 knock-
out mice [15,14]. However, it is still unclear which specific
brain substrates are involved in mGluR5-mediated regula-
tion of locomotor activity. It has been recently demon-
strated that the knockout of mGluR5 exclusively in the
cortex promotes increased novelty-induced locomotor ac-
tivity [10]. Moreover, when these cortical-specific mGluR5
knockout mice were injected with MPEP intraperitoneally,
they exhibited a pronounced increase in locomotor activity,
which was much greater than that of wild type mice
injected with MPEP [10]. These results indicate that the
role of mGluR5 in locomotor activity might involve the
cross-interaction of different neural substrates.
Thus, to better understand the role of mGluR5 in
motor control and determine which neural substrates
are involved in this regulation we performed stereotactic
microinfusions of MPEP in select brain regions, including
motor and parietal cortex, dorsal and ventral striatum,
hippocampus and olfactory bulb, and submitted mice to
the open field and rotarod apparatus. Our findings indi-
cate that mGluR5 blockage elicit different outcomes in
terms of locomotor activity and motor coordination de-
pending on the brain area injected. Our data suggest that
not only primarily motor neural substrates, but also limbic
and sensory structures are involved in mGluR5-mediated
motor behavior.
Results
In order to determine which brain substrates are involved
in mGluR5-mediated motor control we performed stereo-
tactic microinfusion of the mGluR5 negative allosteric
modulator (NAM), MPEP, which is highly selective for
mGluR5 [16], into specific brain coordinates targeting the
various brain regions where the receptor is vastly
expressed. First, we injected either MPEP 25 nmol/0.5 μL/
side or vehicle into the primary motor cortex, which is a
vital area for the regulation of locomotor activity, and
10 min later, subjected mice to the open field apparatus.
Cannula placement into the primary motor cortex was
confirmed by histology for all tested mice (Figure 1E).
Statistical analyses (two-way ANOVA) indicated that
mGluR5 blockage in the primary motor cortex caused a
decrease in spontaneous locomotor activity when assessed
in the open field apparatus [Interaction: F(11,143) =
1.222, P = 0.2778; time: F(11,143) = 24.05, P < 0.0001;
treatment: F(1,143) = 1.935, P = 0.0088] (Figure 1A). In
addition, total distance traveled by mice injected with
MPEP in the primary motor cortex was smaller than
that of vehicle-injected mice [t(13) = 3.077; P = 0.0044](Figure 1B). It has been demonstrated that MPEP has
anxiolytic-like effects when injected intraperitoneally [12].
Mice exhibiting increased anxiety tend to spend less time
in the central area of the open field arena. Thus, we
sought to determine whether injection of MPEP into the
primary motor cortex would change the extent mice
would walk in the central area of the arena. We found that
the injection of mice with MPEP into the primary motor
cortex did not increase the distance mice travelled in the
center of the open field when compared with vehicle-
injected mice [Interaction: F(11,143) = 1.305, P = 0.2274;
time: F(11,143) = 9.124, P < 0.0001; treatment: F(1,143) =
0.6899, P = 0.4212] (Figure 1C). Moreover, total distance
traveled in the center was also not different between treat-
ments [t(13) = 0.8312; P = 0.2104] (Figure 1D), suggesting
that this brain substrate may not be involved in mGluR5-
mediated anxious behavior in the open field apparatus.
Following open field assessments, mice were trained
on the rotarod for two days. On the third day, mice were
microinfused with either MPEP or vehicle into the motor
cortex and tested for motor coordination on the rotating
rod. MPEP microinfusion in this brain substrate led to de-
creased latency to fall from the rotarod [t(12) = 1.878; P =
0.0424] (Figure 1F). Together, these data indicate that the
inhibition of mGluR5 expressed in the primary motor cor-
tex inhibits locomotion and decreases motor coordination.
In order to further validate the inhibitory effect of
mGluR5 blockage on locomotor activity and motor co-
ordination, we performed microinfusions of another
mGluR5 NAM, MTEP, into the primary motor cortex.
Histological slices were analyzed to confirm cannula
placement for all tested mice (Additional file 1: Figure S1E).
Following injection of either MTEP 25 nmol/0.5 μL/side or
vehicle into the primary motor area, mice were subjected to
the open field apparatus. mGluR5 blockage by MTEP pro-
moted decreased spontaneous locomotion activity when
mice were submitted to the open field apparatus [Inter-
action: F(11,110) = 1.848, P = 0.0543; time: F(11,110) =
6.813, P < 0.0001; treatment: F(1,110) = 14.51, P = 0.0034]
(Additional file 1: Figure S1A) and [t(10) = 3.809; P =
0.0017] (Additional file 1: Figure S1B). On the other hand,
the distance mice traveled in the center of the arena was
not significantly different when comparing mice injected
with either vehicle or MTEP [Interaction: F(11,99) = 1.660,
P = 0.0938; time: F(11,99) = 6.191, P < 0.0001; treatment: F
(1,99) = 9.512, P = 0.0131] (Additional file 1: Figure S1C)
and [t(10) = 1.197; P = 0.1295] (Additional file 1: Figure
S1D). Furthermore, mice injected with MTEP into the pri-
mary motor cortex exhibited decreased latency to fall from
the rotarod, as compared to that of vehicle-injected mice
[t(09) = 1.847; P = 0.0489] (Additional file 1: Figure S1F).
These data demonstrate that the tested mGluR5 NAMs,
MPEP and MTEP, promote decreased motor function
when injected into the primary motor cortex and that
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on motor behavior.
The posterior parietal cortex is an associative cortical
brain region that controls visually guided movements
and spatial orientation and expresses high levels of
mGluR5 [17]. Thus, we decided to test whether MPEP
microinfusion into the posterior parietal cortex could
modify locomotor activity and motor coordination. We
confirmed that cannula was placed in the right position
(Figure 2E). Mice injected with MPEP in the posterior
parietal cortex exhibited the same levels of locomotor
activity as vehicle-treated mice [Interaction: F(11,110) =
0.9575, P = 0.4893; time: F(11,110) = 17.59, P < 0.0001;
treatment: F(1,110) = 0.01287, P = 0.9119] (Figure 2A) and
[t(10) = 0.03184; P = 0.4876] (Figure 2B). Moreover, dis-
tance traveled in the center of the arena was also not dif-
ferent between treatments [Interaction: F(11,110) = 0.8268,
P = 0.6136; time: F(11,110) = 6.668, P < 0.0001; treatment:Figure 1 mGluR5 blockage in the primary motor cortex promotes reductio
distance traveled (A) and the percentage of distance traveled in the center
MPEP (n = 8) measured at 5 min intervals. Graphs show total distance trave
mice injected with either vehicle (n = 7) or MPEP (n = 8) cumulative over 60
vehicle (DMSO 50%) or MPEP (25 nmol/0.5 μL/side) microinfusion into the
Shown is a photomicrography of a representative neutral red stained coron
primary motor cortex coordinates. (F) Graph shows latency to fall from acc
(25 nmol/0.5 μL/side) (n = 7). Each animal was tested in three trials and the
SEM. * indicate significant differences as compared to vehicle-injected miceF(1,110) = 0.01110, P = 0.9182] (Figure 2C) and [t(10) =
0.1054; P = 0.4591] (Figure 3D). In addition, injection of
MPEP into the posterior parietal cortex of mice did not
increase the latency to fall from the rotarod as compared
to vehicle-treated control mice [t(10) = 0.4677; P = 0.3250]
(Figure 2F). Thus, mGluR5 expressed in the posterior par-
ietal cortex appears not to be involved in locomotor
control.
mGluR5 is highly expressed in the striatum, which is
an important region for motor control [18,19]. To inves-
tigate whether mGluR5 expressed in the striatum partic-
ipates in movement regulation, we first performed
stereotactic microinfusions of MPEP 25 nmol/0.5 μL/
side into the dorsal striatum. Histological analyses indi-
cated that cannula was correctly placed at the dorsal
striatum (Figure 3E). Injection of MPEP into the dorsal
striatum promoted a small increase in spontaneous loco-
motor activity, which did not reach statistical significancen of both locomotor activity and rotarod performance. Graphs show
of the apparatus (C) by mice injected with either vehicle (n = 7) or
led (B) and the percentage of distance traveled in the center (D) by
min. Animals were placed in the open field box after 10 min of either
primary motor cortex. Each animal was monitored for 60 min. (E)
al brain section depicting guide cannula placement according to
elerating rotarod by mice injected with either vehicle (n = 7) or MPEP
average latency to fall was determined. Data represent the means ±
(P < 0.05).
Figure 2 mGluR5 antagonism on posterior parietal cortex does not change locomotor activity or rotarod performance. Graphs show distance
traveled (A) and the percentage of distance traveled in the center of the apparatus (C) by mice injected with either vehicle (n = 6) or MPEP (n = 6)
measured at 5 min intervals. Graphs show total distance traveled (B) and the percentage of distance traveled in the center (D) by mice injected with
either vehicle (n = 6) or MPEP (n = 6) cumulative over 60 min. Animals were placed in the open field box after 10 min of either vehicle (DMSO 50%) or
MPEP (25 nmol/0.5 μL/side) microinfusion into the parietal cortex. Each animal was monitored for 60 min. (E) Shown is a photomicrography of a
representative neutral red stained coronal brain section depicting guide cannula placement according to posterior parietal cortex coordinates. (F)
Graph shows latency to fall from accelerating rotarod by mice injected with either vehicle (n = 6) or MPEP (25 nmol/0.5 μL/side) (n = 6). Each animal
was tested in three trials and the average latency to fall was determined. Data represent the means ± SEM.
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13.20, P < 0.0001; treatment: F(1,110) = 4.018, P = 0.0728]
(Figure 3A). However, total distance traveled by animals
injected with MPEP into the dorsal striatum was sig-
nificantly greater than that of animals injected with ve-
hicle [t(10) = 2.005; P = 0.0364] (Figure 3B). We observed
no MPEP-induced difference in the distance mice traveled
in the center of the open field [Interaction: F(11,110) =
1.533, P = 0.1297; time: F(11,110) = 2.147, P = 0.0225; treat-
ment: F(1,110) = 1.572, P = 0.2385] (Figure 3C) and [t(10) =
1.254; P = 0.1192] (Figure 3D) and MPEP treatment did
not alter the latency to fall from the rotarod [t(12) = 0.9155;
P = 0.1890] (Figure 3F). In contrast, animals injected with
MPEP into the ventral striatum (Figure 4E) demonstrated
significantly reduced locomotor activity when compared
to vehicle-treated control mice [Interaction: F(11,110) =
1.675, P = 0.0885; time: F(11,110) = 24.75, P < 0.0001; treat-
ment: F(1,110) = 5.261, P = 0.0447] (Figure 4A) and [t(10) =
2.294; P = 0.0224] (Figure 4B). However, similar to whatwe observed for MPEP treatment of mice in the dorsal stri-
atum, MPEP injection into the ventral striatum did not
modify distance mice traveled in the center of the
open field [Interaction: F(11,110) = 1.135, P = 0.3414;
time: F(11,110) = 6.729, P < 0.0001; treatment: F(1,110) =
0.9410, P = 0.3549] (Figure 4C) and [t(10) = 1.005; P =
0.1693] (Figure 4D). Furthermore, microinfusion of
MPEP into the ventral striatum did not alter perform-
ance on the rotarod apparatus [t(13) = 1.168; P =
0.1318] (Figure 4F). Thus, depending on which region
of the striatum mGluR5 is blocked, the result can be
either hypokinesia or hyperkinesia.
mGluR5 is also expressed at high levels in the hippo-
campus, a brain region that is involved in cognitive func-
tions [20]. However, a number of publications indicate
that this brain structure is also implicated in movement
control [21,22]. Thus, we tested whether antagonism of
mGluR5 activity in the dorsal hippocampus might alter
locomotor activity. MPEP microinfusion into the dorsal
Figure 3 Acute antagonism of mGluR5 on dorsolateral striatum increases locomotor activity. Graphs show distance traveled (A) and the
percentage of distance traveled in the center of the apparatus (C) by mice injected with either vehicle (n = 6) or MPEP (n = 6) measured at 5 min
intervals. Graphs show total distance traveled (B) and the percentage of distance traveled in the center (D) by mice injected with either vehicle
(n = 6) or MPEP (n = 6) cumulative over 60 min. Animals were placed in the open field box after 10 min of either vehicle (DMSO 50%) or MPEP
(25 nmol/0.5 μL/side) microinfusion into the dorsolateral striatum. Each animal was monitored for 60 min. (E) Shown is a photomicrography of a
representative neutral red stained coronal brain section depicting guide cannula placement according to dorsolateral striatum coordinates. (F)
Graph shows latency to fall from accelerating rotarod by mice injected with either vehicle (n = 7) or MPEP (25 nmol/0.5 μL/side) (n = 7). Each
animal was tested in three trials and the average latency to fall was determined. Data represent the means ± SEM. * indicates significant
difference as compared to vehicle-injected mice (P < 0.05).
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ment by histology (Figure 5E). MPEP injection into the
dorsal hippocampus resulted in significantly increased
motor activity of treated mice when compared to vehicle-
treated controls [Interaction: F(11,121) = 0.9099, P = 0.5332;
time: F(11,121) = 9.364, P < 0.0001; treatment: F(1,121) =
7.643, P = 0.0184] (Figure 5A) and [t(11) = 2.765; P =
0,0092] (Figure 5B). However, the distance traveled in the
center of the open field arena was not affected by injection
of MTEP into the dorsal hippocampus [Interaction: F
(11,121) = 0.3386, P = 0.9753, time: F(11,121) = 4.472, P <
0.0001, treatment: F(1,121) = 0.4223; P = 0.5291] (Figure 5C)
and [t(10) = 1.005; P = 0.1693] (Figure 5D). Furthermore,
MPEP microinfusion into the dorsal hippocampus did not
alter latency time to fall for treated mice versus vehicle-
treated control [t(11) = 1.186, P = 0.1304] (Figure 5F). Ac-
cording to these data, mGluR5 expressed in the dorsal
hippocampus appears to be involved in spontaneous loco-
motor activity.The olfactory bulb expresses high levels of mGluR5 and
is a sensory brain area involved in olfaction [23]. Because
the olfactory bulb is not known to be involved in motor
control [24], as a control, we tested whether the antagonist
of mGluR5 in the olfactory bulb would affect locomotor ac-
tivity. Again, cannula placement was confirmed by histology
(Figure 6E). As expected, spontaneous locomotor activity
was not different when comparing mice that had the
olfactory bulb microinfused with either MPEP or ve-
hicle [Interaction: F(11,143) = 0.8878, P = 0.5539, time: F
(11,143) = 24.34, P < 0.0001; treatment: F(1,143) = 0.01356,
P = 0.9091] (Figure 6A) and [t(13) = 0.1383, P = 0.4461]
(Figure 6B). However, surprisingly, injection of MPEP
into the olfactory bulb significantly increased the dis-
tance mice traveled in the center, as compared to that
of vehicle-injected mice [Interaction: F(11,143) = 1.036,
P = 0.4182, time: F(11,143) = 8.539, P < 0.0001, treatment: F
(1,143) = 11.10; P = 0.0054] (Figure 6C) and [t(13) = 2.459, P =
0.0144] (Figure 6D). Moreover, the latency to fall from the
Figure 4 The inhibition of mGluR5 on ventral striatum promotes a reduction in locomotor activity. Graphs show distance traveled (A) and the
percentage of distance traveled in the center of the apparatus (C) by mice injected with either vehicle (n = 6) or MPEP (n = 6) measured at 5 min
intervals. Graphs show total distance traveled (B) and the percentage of distance traveled in the center (D) by mice injected with either vehicle
(n = 6) or MPEP (n = 6) cumulative over 60 min. Animals were placed in the open field box after 10 min of either vehicle (DMSO 50%) or MPEP
(25 nmol/0.5 μL/side) microinfusion into the ventral striatum. Each animal was monitored for 60 min. (E) Shown is a photomicrography of a
representative neutral red stained coronal brain section depicting guide cannula placement according to ventral striatum coordinates. (F) Graph
shows latency to fall from accelerating rotarod by mice injected with either vehicle (n = 8) or MPEP (25 nmol/0.5 μL/side) (n = 7). Each animal was
tested in three trials and the average latency to fall was determined. Data represent the means ± SEM. * indicates significant difference as
compared to vehicle-injected mice (P < 0.05).
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factory bulb [t(12) = 2.126, P = 0,0275] (Figure 6F). Together,
these data suggest that mGluR5 expressed in the olfactory
bulb could be important for motor coordination and anx-
iety behavior.
Discussion
It is well known that mGluR5 is involved in the regulation
of locomotor activity, as it has been demonstrated that both
mGluR5 pharmacological blockage and receptor knockout
results in increased locomotor activity [15,13,14]. However,
the specific brain regions regulating mGluR5-dependent al-
terations in locomotor activity have yet to de delineated. In
the present study, we address that issue by performing
stereotactic microinfusion of the mGluR5 antagonist,
MPEP, into brain areas that express high levels of mGluR5,
including the cortex, striatum, hippocampus and olfactory
bulb (Figure 7), and assessing mouse motor behavior in theopen field and rotarod apparatus. Our results indicate that
the blockage of mGluR5 in neural substrates that are pri-
mary motor, as well as in limbic and sensory structures, can
promote alterations in locomotor activity and motor coord-
ination and balance.
mGluR5 is highly expressed in the brain and its activa-
tion promotes excitation, as this receptor signals
through Gαq/11, promoting activation of PKC and release
of Ca2+ from intracellular stores, as well as positively
modulating excitatory ion channels [5,7,8]. However, re-
sults from our group and others indicate that mGluR5
blockage induces hyperkinesia [13,14]. In addition to that,
mGluR5 knockout mice exhibit a robust hyperkinetic
phenotype [14,15]. Moreover, mGluR5 knockout exclu-
sively in the cortex exhibit increased locomotor activity
[10]. Interestingly, when we blocked mGluR5 with MPEP
in different areas of the cortex, such as motor and parietal
cortex, we obtained opposing results: decreased locomotor
Figure 5 MPEP acute antagonism on dorsal hippocampus induces increased locomotor activity. Graphs show distance traveled (A) and the
percentage of distance traveled in the center of the apparatus (C) by mice injected with either vehicle (n = 6) or MPEP (n = 7) measured at 5 min
intervals. Graphs show total distance traveled (B) and the percentage of distance traveled in the center (D) by mice injected with either vehicle
(n = 6) or MPEP (n = 7) cumulative over 60 min. Animals were placed in the open field box after 10 min of either vehicle (DMSO 50%) or MPEP
(25 nmol/0.5 μL/side) microinfusion into the hippocampus. Each animal was monitored for 60 min. (E) Shown is a photomicrography of a
representative neutral red stained coronal brain section depicting guide cannula placement according to dorsal hippocampus coordinates. (F)
Graph shows latency to fall from accelerating rotarod by mice injected with either vehicle (n = 6) or MPEP (25 nmol/0.5 μL/side) (n = 7). Each
animal was tested in three trials and the average latency to fall was determined. Data represent the means ± SEM. * indicates significant
difference as compared to vehicle-injected mice (P < 0.05).
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motor cortex and no change in locomotion in the case of
injection into the posterior parietal cortex. Thus, mGluR5
blockage in different cortical sub-areas can elicit different
motor outcomes, which could be due to the neural con-
nections that these brain areas establish. Moreover,
mGluR5 is expressed not only in glutamatergic neurons,
but also in inhibitory neurons and glia [25,26]. Thus, it is
possible that the antagonism of mGluR5 in the whole
brain results in increased locomotor activity due to the
interplay of the various neural circuitries. Interestingly,
from our data it is clear that even regions that are not pri-
mary motor substrates, but limbic and sensory structures,
appear to affect locomotor activity via mGluR5, which
highlights the complexity of the neural networks that re-
sults in a specific animal behavior such as movement. Fur-
thermore, there are other neural substrates that are
important for motor control regulation, including thecerebellum, which has a crucial role related to balance and
locomotion, and that do not express mGluR5 [8]. In this
case, the underlying mechanism might not involve
mGluR5 activation, but could involve other receptors also
important for motor regulation [27].
The antagonist of mGluR5 activity in the dorsolateral
striatum promoted increased locomotor activity, whereas
receptor blockage in the ventral striatum decreased loco-
motor activity. These data further highlight how region-
specific are the actions of mGluR5 to regulate movement.
The region of the ventral striatum analyzed in this study
corresponds to the nucleus accumbens core, which mainly
receives input from the hippocampus, amygdala and pre-
frontal cortex, playing an important role in motivation
and reward processes, as well as in locomotion [28,29].
The ventral striatum projects mainly to the dorsolateral
part of the substantia nigra pars reticulata (SNr), to the
ventral tegmental area (VTA) and to the substantia nigra
Figure 6 The focal inhibition of mGluR5 on the olfactory bulb alters locomotor performance and distance traveled in the center of the arena.
Graphs show distance traveled (A) and the percentage of distance traveled in the center of the apparatus (C) by mice injected with either
vehicle (n = 7) or MPEP (n = 8) measured at 5 min intervals. Graphs show total distance traveled (B) and the percentage of distance traveled in
the center (D) by mice injected with either vehicle (n = 7) or MPEP (n = 8) cumulative over 60 min. Animals were placed in the open field box
after 10 min of either vehicle (DMSO 50%) or MPEP (25 nmol/0.5 μL/side) microinfusion into the olfactory bulb. Each animal was monitored for
60 min. (E) Shown is a photomicrography of a representative neutral red stained coronal brain section depicting guide cannula placement
according to olfactory bulb coordinates. (F) Graph shows latency to fall from accelerating rotarod by mice injected with either vehicle (n = 7) or
MPEP (25 nmol/0.5 μL/side) (n = 7). Each animal was tested in three trials and the average latency to fall was determined. Data represent the
means ± SEM. * indicate significant differences as compared to vehicle-injected mice (P < 0.05).
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the ventral striatum could: 1) disinhibit the SNc, which
can stimulate (dopaminergic projection) the motor cortex
and modulate the striatum; and 2) disinhibit the SNr,
which can inhibit (GABAergic projection) thalamus-
cortex [30]. Our results showing that MPEP injection into
the ventral striatum diminishes locomotor activity are in
agreement with the hypothesis that mGluR5 may be in-
volved in the ventral striatum output to the SNr (Figure 7).
The dorsal striatum, on the other hand, corresponds to
the caudate and putamen in primates and closely regulates
sensorimotor behavior [31]. The striatum dorsal portion
can be further divided into two sub-regions: 1) an external
portion (dorsolateral), which corresponds to the primate
putamen and receives projections from the sensorimotor
cortex and thalamus, and 2) an internal portion (dorsome-
dial), which is homologous to the primate caudate and re-
ceives projections from the prefrontal and associativecortex, amygdala and hippocampus [32,19]. Functionally,
the dorsalmedial striatum is more similar to the ventral
striatum. The dorsolateral area, which is the main striatal
area involved in motor function, projects to the ventrolat-
eral SNr [33]. Thus, mGluR5 inhibition in the dorsolateral
striatum could disinhibit the SNr, which can promote
thalamo-cortical inhibition. However, another dorsolateral
striatum output target is the globus pallidus externa
(GPe). In this case, MPEP injection into the dorsolateral
striatum could disinhibit the GPe, which then can inhibit
the subthalamic nucleus (STN) that will diminish activation
of the SNr/globus pallidus interna (GPi) with consequent
decrease in thalamus-cortical inhibition (Figure 7) [30]. In
this case the result would be increased locomotor activity,
as found in our current study. However, there are many in-
trinsic circuits within the basal ganglia and a much higher
level of complexity in terms of the variety of neurotransmit-
ters involved in locomotor activity. Therefore, additional
Figure 7 Potential neural pathways involved in motor behavior modulated by mGluR5. (A) Shows schematic representing CNS regions where
MPEP injections were performed and the possible neural pathways involved in the behavioral findings following mGluR5 blockage. (1) MPEP
injection on the main olfactory bulb (MOB) led to an increase in the distance traveled in the center of the arena and to decreased motor
performance on the rotarod. (2) MPEP injection into the primary motor area (M1) led to a decrease in locomotion in the open field and to
decreased rotarod performance. (3) The blockage of mGluR5 in the dorsolateral striatum (DLStr) led to increased locomotor activity. Inhibition of
mGluR5 by MPEP in DLStr (Green lines) may disinhibit the globus pallidus externa (GPe), which can then inhibit the subthalamic nucleus (STN).
STN inhibition will diminish activation of the substantia nigra pars reticulata (SNr)/ globus pallidus interna (GPi), with consequent disinhibition of
the thalamus (Th) – cerebral cortical (Cx) circuit, resulting in increased locomotor activity. (4) The blockage of mGluR5 in the ventral striatum (VStr)
by MPEP (pink lines) may disinhibit the SNr, which can inhibit Th-Cx projections, resulting in decreased locomotor activity. (5) mGluR5 inhibition in
the dorsal hippocampus (dHPC) resulted in increased locomotor activity. The dHC projects to the VStr, which is involved in motor control (orange
lines). Moreover, it has been shown that the dHPC has intrahippocampal projections connecting it to the ventral hippocampus (vHPC). (6) MPEP
injections on the posterior parietal cortex (V2MM) elicited no alteration on behavioral tests. (B) Shows summary results of the behavioral findings
for each neural substrate injected with MPEP. Blue circles indicate brain regions that highly express mGluR5 and that were injected with MPEP.
Colorful lines (green, pink and orange) represent neural circuits. Filled lines indicate activated circuits and dotted lines indicate inhibited circuits.
Excitatory pathways are depicted as arrows and inhibitory pathways as blocked lines.
Guimaraes et al. Molecular Brain  (2015) 8:24 Page 9 of 13experimentation focusing on the role of other neurotrans-
mitters, such as acetylcholine and dopamine, will be neces-
sary to determine which circuits and brain areas are
underlying the locomotor alterations observed when MPEP
was injected in the ventral and dorsal striatum.
Our data indicate that mGluR5 blockage in the hippo-
campus, which is a brain substrate well known for its role
on memory and cognition [34,20], produces hyperkinesia.
One potential hypothesis to explain this observation is that
hyperkinesia following hippocampal mGluR5 blockage
might reflect a deficit in the animal’s habituation to the en-
vironment due to disruption of hippocampal-dependent
spatial and contextual memory [35,36]. However, thishypothesis does not adequately explain our current find-
ings, as a habituation deficit would be reflected by a delayed
onset of hyperactivity and our data demonstrated that hip-
pocampal injection of MPEP led to immediate hyperactivity
(Figure 5A). Another possibility is that mGluR5 blockage in
the hippocampus modulates locomotor activity directly.
The hippocampus can be divided into dorsal and ventral
hippocampus [20,19]. In terms of function, the dorsal
hippocampus appears to be involved in spatial learning and
memory, whereas the ventral hippocampus is important for
motor functions, as it directly connects to the prefrontal
cortex, amygdala and ventral striatum (nucleus accumbens)
[37,38]. However, the dorsal hippocampus also exhibit an
Guimaraes et al. Molecular Brain  (2015) 8:24 Page 10 of 13output to the ventral striatum (Figure 7) [39], which could
implicate this neural substrate in motor control. Moreover,
there are intrahippocampal projections connecting dorsal
and ventral hippocampus [40], which implies that the ven-
tral role on motor modulation can be influenced by dorsal
hippocampus manipulation (Figure 7). Supporting this hy-
pothesis, a previous study demonstrated that an ischemic
insult that promotes loss of 80% of the dorsal hippocampus
(CA1 region) elicits hyperkinesia in rodents [21]. Moreover,
microinfusion of the NMDA receptor antagonist, MK801,
into the ventral and dorsal hippocampus promotes in-
creased locomotor activity in the open field apparatus, al-
though the increase promoted by dorsal hippocampus
MK801 infusion was lesser than that of ventral infusion
[41,42]. The hyperactivity following hippocampal lesions
has been proposed to reflect the loss of inhibitory control
over the dopaminergic tonus in the ventral striatum [43].
In agreement with this idea, our results demonstrate that
MPEP injection into the dorsal hippocampus promoted in-
creased locomotor activity, whereas injection of MPEP into
the ventral striatum elicited hypokinesia.
To our surprise, injection of MPEP into the olfactory
bulb, which is a primary olfactory sensory region of the
brain, led to decreased latency to fall from the rotarod
and increased distance traveled in the center of the open
field arena. Nevertheless, it has been demonstrated that
olfactory bulbectomy can alter exploratory behavior,
locomotor activity and social interaction [44,45]. Moreover,
different authors have reported that olfactory bulbectomy
increases anxiety and that anxiolytic drugs normalize this
behavior [44,46,47]. However, when submitted to the social
interaction test, which is a well-accepted paradigm to meas-
ure anxiety, olfactory bulbectomized mice exhibited in-
creased social interaction [44]. It is well established that
intraperitoneally-injected MPEP has anxiolytic-like effects
[12] and our data indicate that MPEP injection into the ol-
factory bulb seems to decrease anxiety, as mice spent
more time in the center of the arena. These data indicate
that mGluR5 might have a role in anxious behavior via ol-
factory bulb. However, the distance traveled in the center
of the arena per se is not enough to determine whether
MPEP is capable of decreasing anxiety via olfactory bulb
and additional anxiety tests will be required to further in-
vestigate this issue.
Conclusions
In conclusion, our results highlight the importance of
mGluR5 in modulating motor behavior in a variety of
brain regions. Our data indicate that regulation of loco-
motor activity seems to involve well known primary
motor brain areas, as well as somatosensory and limbic
brain structures (Figure 7). Moreover, to our surprise, brain
substrates that are important for mGluR5-mediated regula-
tion of locomotor activity appears to differ from those thatmodulate motor coordination via mGluR5. For instance,
the only MPEP-injected brain region that exhibited both
locomotor activity and rotarod alterations was the primary
motor cortex. Interestingly, although it is very clear from
the literature that the striatum is important for motor co-
ordination [48,49], MPEP injection into the dorsal and ven-
tral striatum did not modify rotarod performance, even
though it altered locomotor activity. Thus, our data support
the idea that dissecting the neural circuits involved in
mGluR5-mediated motor behavior regulation is very im-
portant to better understand the physiological role of this
receptor, as well as its role in a number of diseases that
involve motor alterations, including Huntington’s disease.
Future studies will be necessary to further elucidate the




2-methyl-6-(phenylethynyl)-pyridine (MPEP) and 3-[(2-
methyl-1,3-thiazol-4-yl) ethynyl] pyridine (MTEP) were
purchased from Tocris Bioscience (Bristol, UK). Di-
methyl sulfoxide (DMSO) and paraformaldehyde were
purchased from Sigma Aldrich (St. Louis, MO, U.S.A.).
Neutral red A.R. was purchased from Himedia Labora-
tories (Mumbai, MH, India). Glass microscope slides
(25,4 mm x 76,2 mm) were from Global Glass (Beilun,
ZHE, China). Sucrose was purchased from Synth (Diadema,
SP, Brazil) and saline solution 0.9% (NaCl) from Equiplex
(Aparecida de Goiânia, GO, Brazil). Ketamine hydrochlor-
ide and xylazine hydrochloride were purchased from Syntec
(Cotia, SP, Brazil) and flunixin meglumine - Banamine®
from Schering-Plough (Kenilworth, NJ, U.S.A). The zinc ce-
ment and dental acrylic were purchased from Coltene (São
Jose, SC, Brazil) and cephalexin from Medley (Brasilia, DF,
Brazil). The polyethylene tubing (PE20) was purchased
from Tygon® Tubing (Ohio, U.S.A.).Animals
This study was conducted using male C57/BL6 mice
(25-30 g) that were purchased from the animal facility
(CEBIO) located at the Universidade Federal de Minas
Gerais (UFMG). Mice were housed in an animal care
facility at 23°C on a 12 h light/12 h dark cycle with
food and water provided ad libitum. The number of
mice, with correctly placed cannula, used for the pri-
mary motor cortex injection experiments was 27 (7 ve-
hicle and 8 MPEP and 6 vehicle and 6 MTEP), for the
posterior parietal cortex it was 12 mice (6 vehicle and 6
MPEP), for the dorsolateral striatum it was 14 mice (7
vehicle and 7 MPEP), for the ventral striatum it was 15
mice (8 vehicle and 7 MPEP), for the dorsal hippocam-
pus it was 13 mice (6 vehicle and 7 MPEP) and for
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The experimental procedures used in this study re-
ceived approval from CETEA-UFMG (Ethics Commit-
tee for Animal Experimentation - UFMG), protocol
#274/2011.
Drugs
MPEP was diluted in vehicle consisting of 50% dimethyl
sulfoxide (DMSO) in saline (0.9% NaCl) and MTEP was
diluted in vehicle consisting of saline only. Each neural
structure was microinfused with either vehicle, 25 nmol
MPEP or 25 nmol MTEP, in a final volume of 0.5 μL per/
side, which is in accordance with published data [50-53].
Cannula implantation and microinfusion
Surgery procedures were performed according to [54].
Mice were not handled before surgery. Before surgery
procedures, animals were anesthetized with ketamine
(80 mg/kg) and xylazine (10 mg/kg) intraperitoneally (i.p.)
and placed in the stereotaxic apparatus (Stoelting, Italy).
Bregma and lambda were aligned at the same horizontal
and vertical planes. Small holes (0.7 mm) were drilled di-
rected into the skull according to the stereotaxic coordi-
nates (Figure 8). Bilateral guide cannulae with metal
occluding rods were fixed into the skull with zinc cement
followed by dental acrylic. Following cannula implantation,
mice received a single intramuscular dose of flunixin
meglumine (Banamine®, 0.3 mg/kg) and two doses of ceph-
alexin (72 mg/kg) orally. Time of post-surgical recovery
was 4 to 5 days before the start of behavioral testing. ToFigure 8 Description of stereotaxic coordinates from bregma and featuresperform drug microinfusions, mice were gently immobi-
lized and positioned for removal of the metal occluding
rods and coupling of an injector cannula (30G, 8 mm) to
the guide cannula. All drugs were infused in a volume of
0.5 μL/side. The microinfusion pump was made through a
polyethylene tubing (PE20) connected to a 10 μL syringe
(Hamilton, U.S.A.). Drugs were injected bilaterally in
specific brain regions (Figure 8) at a rate of 0.5 μL/min.
Injector cannula remained in place for 1 min after infu-
sion to avoid diffusion of the drug through the guide
cannula. Animals were subjected to behavioral tests
10 min after removal of the injection cannula.
Histology
At the end of the behavioral experiments, mice were eu-
thanized and their brains were removed and stored in
10% paraformaldehyde for two days, followed by three
days in 30% sucrose. 100 μm thick coronal sections were
obtained using cryostat (−20°C). Slices were stained with
neutral red and visualized by light microscopy. Only
mice with correct placement of cannula were included
in statistical analyses.
Open field test
Spontaneous locomotor activity was assessed using an
automatic open field apparatus (LE 8811 IR Motor Ac-
tivity Monitors PANLAB, Harvard Apparatus; Spain),
with acrylic box dimension of 450 x 450 x 200 mm
(width x depth x height). All experiments using open
field apparatus were performed during the light cycle.of the guide cannula and injector.
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room for at least 60 min. 10 min after drug infusion, ani-
mals were placed in the open field apparatus and the hori-
zontal activity (distance traveled) was measured during
60 min. Quantification of the total activity was calculated
using the ACTITRACK program.
Rotarod test
Mice training and behavioral testing on the rotarod system
(Insight, Ribeirao Preto, Brazil) were performed during the
light cycle. Mice were habituated to the behavioral testing
room for at least 60 min. Initially, animals were submitted
to the training protocol on the rotarod for 2 days, when
mice were placed on the rotating cylinder for 2 min in the
first five speeds ranging from 5 to 19 rotations per min. On
the third day, which was the testing day, mice were injected
with either vehicle or drug and, 10 min later, placed on the
rotarod apparatus. The acceleration protocol was per-
formed in three independent experiments with an interval
of 10 min between trials. If mice fell in the first 10 seconds,
they were immediately relocated to the apparatus and
count was restarted. The latency to fall from the rotating
cylinder was recorded, and the average obtained from the
three trials was used for analysis. The time limit for mice to
remain on the rotarod was up to 300 seconds. After this
period, mice were removed from the apparatus.
Statistical analysis
Means ± SEM are shown for the number of animals indi-
cated in figure legends. GraphPadPrism® version 5
(GraphPad Software Inc., San Diego, USA) software
was used to analyze data for statistical significance and
for curve fitting. Statistical significance was determined
by analysis of variance (ANOVA, repeated measures)
and Student’s t-test and were considered significant
when p < 0.05.Additional file
Additional file 1: Figure S1. MTEP blockage of mGluR5 in the primary
motor cortex reduces both locomotor activity and rotarod performance.
Graphs show distance traveled (A) and the percentage of distance
traveled in the center of the apparatus (C) by mice injected with either
vehicle (n = 6) or MTEP (n = 6) measured at 5 min intervals. Graphs show
total distance traveled (B) and the percentage of distance traveled in the
center (D) by mice injected with either vehicle (n = 6) or MTEP (n = 6)
cumulative over 60 min. Animals were placed in the open field box after
10 min of either vehicle (saline 0.9% NaCl) or MTEP (25 nmol/0.5 μL/side)
microinfusion into the primary motor cortex. Each animal was monitored
for 60 min. (E) Shown is a photomicrography of a representative neutral
red stained coronal brain section depicting guide cannula placement
according to primary motor cortex coordinates. (F) Graph shows latency
to fall from accelerating rotarod by mice injected with either vehicle
(n = 6) or MTEP (25 nmol/0.5 μL/side) (n = 5). Each animal was tested in
three trials and the average latency to fall was determined. Data represent
the means ± SEM. * indicate significant differences as compared to
vehicle-injected mice (P < 0.05).Abbreviations
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